www.3d-cellculture.com Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

ACADEMIC & GROUP DISCOUNTS AVAILABLE

REGISTER BY 31ST OCTOBER AND SAVE £400REGISTER BY 3OTH NOVEMBER AND SAVE £200REGISTER BY 16TH DECEMBER AND SAVE £100

@SMIPHARM

SMi proudly present their inaugural conference on…

3D Cell Culture Technological innovation and clinical success

22nd - 23rd

FEB 2017Copthorne Tara Hotel, London, UK

HIGHLIGHTS IN 2017: • Updates from Roche on patient specifi c screens in

disease modelling • Drug discovery and target validation case study with

AstraZeneca • Insights into high throughput screening, and the use

of CRISPR in 3D cultures from Novartis • Harnessing organoid technology for personalised

models of drug discovery with the HUB • Hear GlaxoSmithKline on the use of 3D cell culture in

toxicity investigations • Compare the benefi t and potential of 3D cell culture

over 2D cell culture with our chair, Stefan Przyborski

PLUS ONE INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPTuesday 21st February 2017, Copthorne Tara Hotel, London, UK

Bio-printing08.30am – 13.00pm

Leader: William Whitford, Strategic Solutions Leader, GE Healthcare Life Sciences

Sponsored by

CHAIRMAN: Stefan Przyborski, Professor of Cell Technology, Durham University

Robert Vries, Managing Director, Hubrecht Organoid Technology Foundation

FEATURED SPEAKERS: • Louise Bisset, Senior Biologicals Quality Assessor, MHRA • Radoslaw Polanski, Senior Research Scientist, AstraZeneca • Olaf Galuba, Scientist, Novartis • Christopher Schofi eld, Investigator, GlaxoSmithKline • Reyk Horland, Head of Business Development, TissUse

3D Cell Culture Day One | Wednesday 22nd February 2017

08.30 Registration & Coffee

09.00 Chairman’s Opening Remarks Stefan Przyborski, Professor of Cell Technology,

Durham University

OPENING ADDRESS 09.10 An introduction to 3D methods; Challenges, changes,

and the relationships between science and technology • 2D vs 3D cell culture debate • Review of alternative approaches and the

development of new technologies • Challenges facing 3D culture methods, in terms of

technologies available and methods used • Showcase applications where 3D technology makes

a difference • Future perspective for 3D cell culture technology

and further development Stefan Przyborski, Professor of Cell Technology,

University of Durham

09.50 Bridging the gap between 2D and in vivo: tumour spheroid-based assays for target validation and screening

• Drug discovery project-related examples of the 2D-3D disconnection with in vivo validation

• Application of a 3D culture technique for analysis of a functional predictive biomarker for the IAPi/TRAIL combination treatment as an alternative to the analysis of expression of single or multiple biomarkers in highly redundant cell death pathways

• Generation of best practice guidelines and development of the platform for screening in tumour spheroids

Radoslaw Polanski, Senior Research Scientist, AstraZeneca

10.30 Morning Coffee

SPOTLIGHT SESSION11.00 Emerging technologies in 3D cell culture for

drug discovery • The potential of 3D culture is dependent on

and symbiotic with technology development • Highlighting of emerging techniques available, focus

on CRISPR and microfl uidic techniques; overview and particular benefi ts in relation to 3D culture

• Current challenges to adoption of new technologies, why are new methods slow to be adopted?

Oliver Chao, Head of Emerging Biomedical Sciences, Sanofi

11.40 Developing IPS cell lines for disease modelling • How using IPS cell lines refi nes disease modelling – patient

specifi c screens • Validating 3D models; can we prove that 3D is indeed

an improvement and is physiology more relevant than previous methods?

• Overview of STEMBANCC Carlo Cusulin, Postdoctoral Researcher, Roche

12.20 Networking Lunch

13.30 HipSci and the ‘Stem cell hotel’, an innovative platforms for collaborative phenotyping

• Stem cells, high content analysis, drug discovery and disease models

• The ‘Human induced pluripotent stem cells initiative’ • Collaborative phenotyping Davide Danovi, Director at the Centre for Stem Cells and

Regenerative Medicine, King’s College London

CASE STUDY NO. 114.10 CRISPR engineered organoids for modelling genetic and

infectious brain disease • Recent genetic advances allow us to rapidly produce

isogenically-controlled disease stem cell lines • These diseases manifest in cerebral organoids similarly to

in the developing human brain • Advanced imaging and sequencing methods allow us

to closely investigate disease and treatment effects on development

• Similar engineering techniques allow precise investigation of interactions between the specifi c proteins and infectious disease

Max Salick, Postdoctoral Researcher, Novartis

14.50 Afternoon Tea

15.20 Human in vitro 3D lung models for effi cacy and toxicity assessment • Long term monitoring of effect on respiratory tract • Disease models (Asthma; COPD; CF and Lung cancer) • How predictive are in vitro 3D human lung models? Samuel Constant, Founder & COO, Epithelix, Founder &

CEO, OncoTheis

16.00 Using 3D spheroids and microtissue methods to investigate hepatotoxicity

• Exploring a complex culture methods using patient liver cells • How does this compare to in vivo models • Moving forward to screening of compounds – how to

achieve this? Christopher Schofi eld, Investigator, GlaxoSmithKline

16.40 Chairman’s Closing Remarks and Close of Day One

NOVEL APPROACHES TO DISEASE MODELLING

TRANSLATING FROM 2D INTO 3D

Register online at www.3d-cellculture.com

MARKETING OPPORTUNITIESWant to know how you can get involved?

Interested in promoting your services to this market? Contact Honey De Gracia SMi Maketing on

+44 (0) 20 7827 6102 or email: hdegracia@smi-online.co.uk

CELLON is a rapidly growing company, established in 1987 to provide products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Our success to-date has been built upon an understanding of the requirements this demanding business sector - which has lead to the formation of many collaborative relationships with our customers. Such partnerships have enabled us to develop a range of products to meet specifi c industry needs - in unique, often revolutionary, ways. www.cellon.lu

DISEASE MODELLING WITH IPS CELL LINES

LETTER FROM OUR CHAIR

Dear participants, Three dimensional (3D) cell culture has amazing potential to revolutionise the way in which we grow cells in the laboratory. The gradual transition from conventional two dimensional (2D) culture to the development and use of 3D in vitro models of cells and tissues has already implemented astonishing changes to the way we are able to screen for compounds and new drugs, assess the safety of chemicals, and model diseases to further understanding of their pathology and treatments.

The application of advanced cell technologies has enabled the ability to mimic the structure and function of cells and tissues in vivo such that the growth conditions provide more representative models of real tissue. There is no doubt that 3D cell culture is a pivotal technique in modern science and a platform for innovation and inspiration.

The development of such technology is not without its challenges however. Harnessing the full potential of 3D cell culture involves closer and closer resemblance to in vivo conditions. It may be that this is inherently impossible, however the continued development of supporting technology and refi ned techniques will undoubtedly implement improvement in coming years. This is an exciting and rapidly developing fi eld of interest that relies on recognising and addressing the existing challenges, forecasting challenges to come, and identifying and adopting best practice.

In a competitive industry like ours, let us appreciate the unique opportunity offered by this event to share our successes and stories of 3D cell culture, to benchmark, and to use the knowledge and understanding gained here to shape future work.

Stefan Przyborski Professor of Cell Technology

Durham University

Sponsored by SPONSORSHIP AND EXHIBITION OPPORTUNITIESSMi offer sponsorship, exhibition, advertising and branding

packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist

to entertain, enhance and expand your client base within the context of an independent discussion specifi c to your industry. Should you wish to join the increasing number of companies benefi ting from sponsoring our conferences

please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

3D Cell Culture Day Two | Thursday 23rd February 2017

08.30 Registration & Coffee

09.00 Chairman’s Opening Remarks Robert Vries, Managing Director, Hubrecht Organoid Technology Foundation

OPENING ADDRESS 09.10 EU Regulatory considerations for the use of cells in drug

manufacturing (quality focus) • Using culture cells in the development and

manufacture of medicinal products • General regulatory perspective on the use of 3D

cultured cells • Manufacturing requirements for clinical trials/MAA Louise Bisset, Senior Biologicals Quality Assessor, MHRA

09.50 3D organoid cultures: a personalised model in drug discovery as well as companion diagnostics

• Increasing the use of patient-derived cultures in preclinical development has the potential to identify, and eliminate, drugs likely to fail in preclinical trials

• High failure rates remains one of the greatest challenges, and barriers, to pharmaceutical drug development

• Using 3D and organoid biobanks to develop preclinical drug development tools and clinical personalised diagnostics

• The use of organoid models has already lead to successful patient specifi c treatments of Cystic Fibrosis

Robert Vries, Managing Director, Hubrecht Organoid Technology Foundation

10.30 Morning Coffee

CASE STUDY NO. 211.00 Screening of Mouse Intestinal Crypt Cultures:

A simple readout for complex biology • Case study: How mouse intestinal crypt cultures have

been adapted to enable high throughput screening • In this system, isolated crypts form “organoid structures”

with a histological hierarchy recapitulating in vivo small intestinal epithelium were used to screen a focused library of compounds for their ability to help the crypts recover from irradiation

• A number of challenges facing the implementation of such assays (such as handling Matrigel, the limits of miniaturisation and assay reproducibility) will be discussed

• Screening allowed the identifi cation of tool compounds with which to help characterise the organoid cultures, subsequently this revealed subtle changes in the organoid response over time. Preliminary characterisation of this change will be described

Olaf Galuba, Scientist, Novartis

SPOTLIGHT SESSION11.40 Multi-Organ on a chip technologies; potential

impact on predictive substance testing • ‘Human-on-a-chip’ technology allows us to

closely study organoid interaction • Allows more representative drug toxicity and

effi cacy screening. Could this be the end of preclinical trials as we know them?

• Closing the gap between in vivo and in vitro; the importance of highly physiologically relevant cultures and microenvironments

Reyk Horland, Head of Business Development, TissUse

12.20 Networking Lunch

13.30 Organ printing and the potential of guided angiogenesis • Larger printed tissues require cells capable of

angiogenesis in order to function, success in achieving functional vasculature has so far been limited

• Developing both appropriate microfl uidics and the in vitro culture media needed for the production of the pre implanted scaffolds remains a challenge

• Future potential; transplants, regenerative medicine, printing in the fourth dimension

William Whitford, Strategic Solutions Leader, GE Healthcare Life Sciences

14.10 Leaving 2D behind – considerations and approaches to translating cell therapy manufacturing into 3D

• Clinical and regulatory implications of transitioning methods from 2D to 3D

• How does cell type affect optimal method used • Manufacturing considerations Eytan Abraham, Head of Research & Technology for

Emerging Technologies, Lonza 14.50 Afternoon Tea

15.20 Automatic mechano-profi ling of cells – A new angle on cancer cell assays

• A short introduction to mechano-biology • Basic measuring techniques for cell mechanics – like 3D

micro-structured cell culture substrates • Automatic mechano-profi ling platform technology (and

its potential for bone cancer prognosis) Nils Goedecke, CEO & Co-Founder, Microduits

16.00 Fast 3D imaging in multiwell plates • Introduction to light sheet-based fl uorescence

microscopy and oblique plane microscopy (OPM) for high speed 3D imaging in multiwell plates

• Examples of experimental data showing readouts of FRET biosensors in multicellular spheroids, including time-lapse 3D imaging in multiwell plates

• An overview of initial steps towards developing image analysis approaches enabling 3D imaging cytometry in multiwall plates

• Discussion of future challenges in data analysis, storage and curation

Chris Dunsby, Reader in Biomedical Optics, Imperial College London

16.40 Chairman’s Closing Remarks and Close of Day Two

ORGAN PRINTING AND ORGAN ON A CHIP

TECHNOLOGY UPDATE AND MANUFACTURING CONSIDERATIONS

Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

Supported by

Offi cial Media Partners

ORGANOID TECHNOLOGY

Offi cial Publications

Bio-printing

Leader: William Whitford, Strategic Solutions Leader,

GE Healthcare Life Sciences

HALF-DAY PRE-CONFERENCE WORKSHOPTuesday 21st February 2017

08.30 – 13.00Holiday Inn Kensington Forum, London, UK

Overview of Workshop:This workshop will cover and discuss 3D bio-printing, answering emerging questions and challenges to this young and exciting fi eld. Our workshop leader is a renowned and appraised expert on bio-printing theories and methods, and welcomes discussion, questions and speculation as to where this technique could lead, and what it means for the future of research, diagnostics, modelling and regenerative medicine. There will also be a feature on the recent development of 4D bio-printing; its principles, context and future.

Reasons to attend:• See the many biological and medical implementations

of “bioprinting”• Hear proposed defi nitions and applications of 4D

bioprinting• Understand the design elements to an optimised “bioink”• Consider the ethical and regulatory issues in organ

printing• Participate in an interactive roundtable discussion on

bioprinting

Programme:08.30 Registration and Coffee09.00 Introduction: what is bio-printing? • How have sponsors employed and defi ned

the term • How do we distinguish - 3D/4D printing - 3D/4D bio-printing - 3D/4D biomaterial printing - Biomimetic 4D printing09.20 Uses and applications • Current printing equipment and materials • When will be ready for a codifi ed “Best Practices” • Applications being accomplished in each area

right now • Challenges to bio-printing in research,

diagnostics, modelling and medicine10.00 Discussion – Ethical and regulatory issues 10.30 Morning Coffee11.00 Looking to the future: how do we adopt and

implement wide use of 4D Bio-printing methods? • Solutions to technical needs and approaches

for especially complex tissues and organs • Future approaches to bio-inks, nano-particles,

-tubes and -fi bers • Cell viability maintenance or progression • Printing resolution, neural and vascular

networks • Printing cartilage and osteochondral tissues • Overcoming challenges to 4D bio-printing12.00 Discussion 13.00 Workshop leader’s comments and close

of the workshop

About the Workshop Leaders:Bill Whitford is Strategic Solutions Leader, GE Healthcare in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company as an R&D Leader developing products

supporting protein biological and vaccine production in mammalian and invertebrate cell lines. Products he has commercialized include defi ned hybridoma and perfusion cell culture media, fed-batch supplements and aqueous lipid dispersions. An invited lecturer at international conferences, Bill has published over 250 articles, book chapters and patents in the bioproduction arena. He now enjoys such activities as serving on the editorial advisory board for BioProcess International.

About the Organisation:GE Healthcare Life Sciences provides expertise and tools for a wide range of applications, including basic research of cells and proteins, drug discovery research, as well as tools to support large-scale manufacturing of biopharmaceuticals.

Sponsorship and Exhibition OpportunitiesSMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specifi c to your industry.

Should you wish to join the increasing number of companies benefi ting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

OCTOBER

European Market Access, Pricing & Reimbursement in Pharma10th - 11th October 2016London, UK

Orphan Drugs19th - 20th October 2016London, UK NOVEMBER

Superbugs & Superdrugs USA14th - 15th November 2016New Jersey, USA

Biosimilars USA16th - 17th November 2016New Jersey, USA

DECEMBER

Cold Chain Distribution12th - 13th December 2016London, UK

JANUARY

Pharmaceutical Microbiology18th - 19th January 2017London, UK

Social Media In The Pharma Industry18th - 19th January 2017London, UK

Pre-Filled Syringes Europe18th - 19th January 2017London, UK FEBRUARY

Parallel Trade6th - 7th February 2017London, UK

3D Cell Culture22nd - 23rd February 2017London, UK

RNA Therapeutics22nd - 23rd February 2017London, UK MARCH

Superbugs & Superdrugs - A Focus on Antibacterials20th - 21st March 2017London, UK

Paediatric Clinical Trials20th - 21st March 2017London, UK

Drug Discovery27th - 28th March 2017London, UK

Asthma & COPD29th - 30th March 2017London, UK APRIL

Controlled Release3rd - 4th April 2017London, UK

Adaptive Designs3rd - 4th April 2017London, UK

Pre-Filled Syringes East Coast26th - 27th April 2017Boston, USA MAY

Lyophilisation8th - 9th May 2017London, UK

Orphan Drugs Europe15th - 16th May 2017Berlin, Germany

Pharma Logistics and Supply Chain18th - 19th May 2017London, UK

Pain Therapeutics22nd - 23rd May 2017London, UK

Highly Potent Active Pharmaceutical Ingredients22nd - 23rd May 2017London, UK JUNE

Pre-Filled Syringes West Coast5th - 6th June 2017San Diego, USA

Microbiology USA8th - 9th June 2017San Diego, USA

ADMET12th - 13th June 2017London, UK

Immunogenicity12th - 13th June 2017London, UK

BioBanking14th - 15th June 2017London, UK

Molecular Diagnostics 14th - 15th JuneLondon, UK JULY

Allergies6th - 7th July 2017London, UK

Peptides6th - 7th July 2017London, UK

SMi PharmaceuticalForward Planner

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Company VAT Number:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Mobile:

Switchboard:

Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefi ngs we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifi cally to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-220 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment:

□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.

Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder’s Name:

Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.

Card Billing Address (If different from above):

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk

□ Book by 31st October to receive £400 off the conference price□ Book by 30th November to receive £200 off the conference price□ Book by 16th December to receive £100 off the conference price

EARLY BIRD DISCOUNT

I would like to attend: (Please tick as appropriate) Fee Total

□ Conference & Workshop £2098.00 + VAT £2517.60□ Conference only £1499.00 + VAT £1798.80□ Workshop only £599.00 + VAT £718.80

PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional

literature to all conference attendees £999.00 + VAT £1198.80

The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.

□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: events@smi-online.co.uk or fax +44 (0) 870 9090 712

I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total□ Access to the conference documentation

on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00

(or only £300 if ordered with the Document Portal)

Unique Reference Number

Our Reference LVP-220

DELEGATE DETAILS

Terms and Conditions of Booking

PAYMENT

VAT

CONFERENCE PRICES

DOCUMENTATION

VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SY

3D CELL CULTURE Conference: Wednesday 22nd & Thursday 23rd February 2017, Copthorne Tara Hotel, London, UK

Workshop: Tuesday 21st February 2017, London, UK

4 WAYS TO REGISTERwww.3d-cellculture.com

FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK